Search research articles
Contact Us
Filters
Showing results (161-170 of 224) with videos related to
Page
of 23
Sort By:
Oncoimmunology
|
September 14, 2016
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
Steve Boudewijns, Rutger H T Koornstra, Harm Westdorp, et al.
Cancer Gene Therapy
|
May 21, 2005
Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy
Daniëlle A M Heideman, Renée M Overmeer, Victor W van Beusechem, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 27, 2016
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
Steve Boudewijns, Harm Westdorp, Rutger H T Koornstra, et al.
Cancer Immunology, Immunotherapy : CII
|
June 30, 2022
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
Sandra van Wilpe, Shabaz Sultan, Mark A J Gorris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
Charles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
Targeted Oncology
|
July 21, 2019
Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane
Annelieke E C A B Willemsen, Jolien Tol, Nielka P van Erp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2017
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial
Esther W Bouman-Wammes, H Pieter van den Berg, Linda de Munck, et al.
Cancer Research
|
October 18, 2002
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy
Martine L M Lamfers, Jacques Grill, Clemens M F Dirven, et al.
Cancer Research
|
October 19, 2005
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma
Martine L M Lamfers, Davide Gianni, Ching-Hsuan Tung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2007
Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma
Martine L M Lamfers, Sander Idema, Lisette Bosscher, et al.
Page
of 23
Search research articles
Search
Showing results (161-170 of 224) with videos related to
Sort By:
Page
of 23
Oncoimmunology
|
September 14, 2016
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
Steve Boudewijns, Rutger H T Koornstra, Harm Westdorp, et al.
Cancer Gene Therapy
|
May 21, 2005
Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy
Daniëlle A M Heideman, Renée M Overmeer, Victor W van Beusechem, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 27, 2016
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
Steve Boudewijns, Harm Westdorp, Rutger H T Koornstra, et al.
Cancer Immunology, Immunotherapy : CII
|
June 30, 2022
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
Sandra van Wilpe, Shabaz Sultan, Mark A J Gorris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
Charles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
Targeted Oncology
|
July 21, 2019
Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane
Annelieke E C A B Willemsen, Jolien Tol, Nielka P van Erp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2017
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial
Esther W Bouman-Wammes, H Pieter van den Berg, Linda de Munck, et al.
Cancer Research
|
October 18, 2002
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy
Martine L M Lamfers, Jacques Grill, Clemens M F Dirven, et al.
Cancer Research
|
October 19, 2005
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma
Martine L M Lamfers, Davide Gianni, Ching-Hsuan Tung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2007
Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma
Martine L M Lamfers, Sander Idema, Lisette Bosscher, et al.
Page
of 23